ALS 用の AMX0035 の中間サイズ拡張アクセス プロトコル
筋萎縮性側索硬化症 (ALS) の成人患者の治療のために、フェニル酪酸ナトリウム (PB) とタウルルソジオール (TURSO) の固定された組み合わせである AMX0035 を提供する中間サイズの拡張アクセスプロトコル
The Expanded Access Program will provide access and assess the safety of AMX0035 for the treatment of people living with ALS.
調査の概要
詳細な説明
AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the endoplasmic reticulum (ER) and mitochondria. This Expanded Access Program is designed to provide expanded access to AMX0035 for the treatment of people living with ALS and assess safety in diverse populations/stages of ALS over 48 weeks.
研究の種類
拡張アクセス タイプ
- 中規模人口
連絡先と場所
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90033
- University of Southern California
-
Oakland、California、アメリカ、94612
- The Kaiser Permanente Medical Group
-
-
Florida
-
Fort Lauderdale、Florida、アメリカ、33308
- Holy Cross Health
-
Fort Lauderdale、Florida、アメリカ、32608
- Nova Southeastern University
-
Gainesville、Florida、アメリカ、32608
- University of Florida
-
-
Illinois
-
Chicago、Illinois、アメリカ、60614
- Northwestern University
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66103
- University of Kansas Medical Center
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- The Sean M. Healey & AMG Center for ALS Massachusetts General Hospital
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic
-
-
Nebraska
-
Lincoln、Nebraska、アメリカ、68510
- Neurology Associates, P.C. / Somnos Clinical Research
-
-
New York
-
New York、New York、アメリカ、10032
- Columbia University Medical Center
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27705
- Duke University Medical Center
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- University of Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19107
- Thomas Jefferson University Weinberg ALS Center
-
-
Texas
-
El Paso、Texas、アメリカ、79995
- Texas Tech University Health Sciences Center El Paso
-
-
Virginia
-
Richmond、Virginia、アメリカ、23298
- Virginia Commonwealth University
-
-
Washington
-
Seattle、Washington、アメリカ、98195
- University of Washington School of Medicine
-
Seattle、Washington、アメリカ、98122
- Swedish Neuroscience Institute
-
Spokane、Washington、アメリカ、99202
- Providence St. Luke's Rehabilitation Medical Center
-
-
Wisconsin
-
Madison、Wisconsin、アメリカ、53705
- University of Wisconsin
-
-
-
-
-
San Juan、プエルトリコ、00936
- Hispanic Alliance for Research & Translational Research
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Male or female, at least 18 years of age (inclusive);
-
Diagnosis of ALS made by a physician experienced with the management of ALS;
-
>36 months from symptom onset defined as first weakness
-
Capable of providing informed consent;
-
Capable of and willing to follow program procedures.
-
Participants who have established care with a physician experienced in treating patients with ALS involved in the program and will maintain this clinical care throughout the duration of their time in the program.
-
Women of childbearing potential (e.g., not post-menopausal for at least one year or surgically sterile) must agree to use adequate birth control for the duration of the program and 3 months after last dose of AMX0035;
- Women must not be planning to become pregnant for the duration of the program and 3 months after last dose of study drug
-
Men must agree to practice contraception for the duration of the program and for at least 3 months after last dose of program drug;
- Men must not plan to father a child or provide sperm
Exclusion Criteria
-
Currently enrolled in a therapeutic study involving the use of an investigational therapy;
-
Dependence on invasive mechanical ventilation, defined as being unable to lay supine without it, unable to sleep without it, or continuous daytime use; presence of tracheostomy at Screening;
- No current need for tracheostomy or PAV (defined as more than 22 hours daily of mechanical ventilation for more than one week (7 days) or based on the site investigator's judgment; no need anticipated for the next 12 weeks
-
In the judgment of the Investigator, the participant's expected survival is less than 6 months
-
History of known allergy to the following: PB, bile salts, excipient/constituents of the formulation;
-
Abnormal liver function defined as AST and/or ALT >3 times the upper limit of the normal (obtained within 12 weeks from first dose);
-
Renal insufficiency as defined by eGFR <60 mL/min/1.73m2 (obtained within 12 weeks from first dose);
-
Pregnant women or women currently breastfeeding;
-
Current severe biliary disease which may result in the investigator medical judgement in biliary obstruction including for example active cholecystitis, primary biliary cirrhosis, sclerosing cholangitis, gallbladder cancer, gallbladder polyps, gangrene of the gallbladder, abscess of the gallbladder;
-
History of Class III/IV heart failure (per New York Heart Association - NYHA);
-
Participant under severe salt restriction where the added salt intake due to treatment would put the participant at risk, in the Site Investigator clinical judgment;
-
Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed c consent, according to Site Investigator judgment;
-
Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant if they were to participate in the program, according to Site Investigator judgment;
-
Treatment, current or within 90 days from screening with any cell therapies or gene therapies;
-
Implantation of Diaphragm Pacing System (DPS);
-
Anything that, in the opinion of the Site Investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the program;
-
Current or planned exposure to any prohibited medications listed in Section 6.8.1 of the protocol
研究計画
研究はどのように設計されていますか?
協力者と研究者
研究記録日
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- A35-006
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。